Obermatt
See Similar Stocks →

United Therapeutics

NSQ:UTHR · US91307C1027
BiotechnologyLarge

360

76
Medium confidence — indicative
EV / EBIT65
Price / Owner Earnings16
Owner Earnings Yield82
Dividend Yield1
Price/Sales53
EV / Gross Profit69
Price/Book47
Return on Capital92
Cash Return on Capital80
Return on Equity85
EBIT Margin98
Gross Profitability83
Cash Conversion51
Accruals60
Owner Earnings Margin79
Sales growth30
Profit Growth98
Long-Term EPS Growth44
Owner Earnings Growth40
Reinvestment15
Price momentum76
Debt load42
Refinancing89
Debt Payback100
Liquidity100
Analyst ratings30
Opinion Changes57
Price Target Upside37
Market mood100
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

United Therapeutics clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryBiotechnology
SizeLarge
TypePublic Company
ExchangeNASDAQGS
Founded1996
Employees1,218
Websiteunither.com
ISINUS91307C1027
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)S&P MIDCAP (USA)D.J. US Health Care
Themes
Alternative ProteinNeurologyChronic DiseasesStem Cell TherapyCardiovascularImmunologyNephrologyOncologyUtility Scale SolarHepatologyPulmonologyRespiratoryBiomedical EngineeringBiotechnologyPharmaceuticalTherapeutics

Description

United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. The company has approval f…

Analysis

Quality compounder

United Therapeutics Corporation is a quality compounder: a well-run business trading at a price that reflects what it is worth.

The price is expensive. You pay 27.8× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 11% yearly growth; analysts expect 10%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is uncertain. The company scores 12/20 on our value-creation score: creating some value.

What to watch: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
85
20252026

All-time high

88

Jan 2025

All-time low

39

Mar 2026

Average rank

74

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
53
17
—
—
Price/Earnings
14
53
—
—
Price/Book
47
44
—
—
Dividend Yield
1
1
—
—
Value (overall)
7
22
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare United Therapeutics with its peers
MannKind
NMQ:MNKD
24
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Gossamer Bio
NSQ:GOSS
24
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Inhibikase Therapeutics
NAQ:IKT
10
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tenax Therapeutics
NAQ:TENX
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Tectonic Therapeutic
NMQ:TECX
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Halozyme Therapeutics
NSQ:HALO
71
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →